Related Experiment Video

Updated: Aug 12, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

Impact of calcium entry blockers on glomerular injury in experimental hypertension

L D Dworkin1

  • 1Department of Medicine, New York University Medical Center, NY 10016.

Cardiovascular Drugs and Therapy
|October 1, 1990
PubMed

Insights

Chronic kidney disease often progresses to kidney failure. Calcium antagonists may protect kidneys by inhibiting compensatory growth, potentially reducing glomerular sclerosis in experimental models.

Area of Science:

  • Nephrology
  • Experimental Nephrology
  • Renal Pathophysiology

Background:

  • Chronic kidney disease (CKD) frequently advances to end-stage renal failure.
  • Glomerular sclerosis is a key pathological feature in progressive CKD.
  • Intrarenal hypertension and compensatory renal hypertrophy are implicated in CKD progression.

Purpose of the Study:

  • To investigate the role of compensatory renal growth in the pathogenesis of glomerular sclerosis.
  • To evaluate the renoprotective effects of calcium antagonists in experimental models of hypertension and renal insufficiency.

Main Methods:

  • Utilized experimental models of hypertension and renal insufficiency.
  • Assessed the impact of hemodynamic changes on renal function.
  • Examined the relationship between kidney hypertrophy and glomerular sclerosis.
  • Investigated the effects of calcium antagonists on glomerular injury and renal growth.

Main Results:

  • Intrarenal hypertension, resulting from reduced nephron number, is linked to sclerosis.
  • Glomerular hypertrophy is identified as an independent risk factor for glomerular sclerosis.
  • Calcium antagonists demonstrated a reduction in glomerular injury in experimental hypertension models.

Conclusions:

  • Compensatory renal growth, including hypertrophy, may be a critical factor driving glomerular sclerosis.
  • Calcium antagonists show potential for renal protection by inhibiting this compensatory growth.
  • Further research into calcium antagonists could offer new therapeutic strategies for CKD progression.

More Related Videos

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...